Peer Navigation to Improve Engagement in Care for HIV-Positive Men Who Have Sex With Men in Ehlanzeni, South Africa
1 other identifier
interventional
103
1 country
1
Brief Summary
This protocol describes the Cohort Assessment phase of an R34 pilot intervention trial of a Peer Navigation (PN) intervention tailored to the needs of HIV-positive MSM in rural Mpumalanga province South Africa. The PN intervention to be adapted, I-Care, has been implemented among HIV-positive men and women in the general population in North West province, South Africa, by members of this research team.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable hiv
Started Sep 2017
Shorter than P25 for not_applicable hiv
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 21, 2017
CompletedFirst Submitted
Initial submission to the registry
October 24, 2017
CompletedFirst Posted
Study publicly available on registry
March 30, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 29, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 29, 2018
CompletedFebruary 5, 2020
February 1, 2020
9 months
October 24, 2017
February 3, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Viral Suppression
The proportion of participants virally suppressed (HIV RNA \<1000 copies/microliter) in Peer Navigation (Intervention) arm compared to standard of care (SOC) arm.
6 months
Study Arms (2)
Peer Navigation
EXPERIMENTALIndividuals assigned to the PN condition will be assigned to one of 10 PN case managers who will follow an SOP described for initial intake and follow up visits with each participant. Participants will be asked to provide contact information for themselves and up to 3 individuals whom study staff can contact in case they cannot make direct contact with the study participant assigned to PN. PN will meet with their clients at least once monthly to discuss treatment related issues including medication access, side effects, adherence, stigma or discrimination related to HIV or their taking ART medication, etc. Participants will have contact information for their assigned PN and may contact them for reasons related to their treatment between scheduled monthly visits if they choose. All visits with PN will be recorded by the PN. and participants who fail to attend up to 3 scheduled PN appointments will be considered LTFU for the intervention.
Standard of Care
NO INTERVENTIONIndividuals assigned to SOC will be referred directly to the NCHC/RLS staff for treatment initiation or continuation. At intake they will receive standard treatment information per MPDOH guidelines, as well as information about Anova's RLS and Health4Men clinical and psychosocial services available at the NCHC. They will receive monthly text message reminders from study staff to refill ART prescriptions, and a separate reminder in month 6 to schedule complete their 6-month clinical visit. Study staff will verify that participants have picked up medications and attended all scheduled clinical visits by means of chart review and data extraction. Per MPDOH guidelines, individuals who fail to collect medications 3 months in a row, or who fail to attend their 6-month HIV clinical follow-up appointment, will be considered non-engaged and lost to follow up (LTFU).
Interventions
Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
Eligibility Criteria
You may qualify if:
- Biological male;
- Age \>=18 years;
- Self-identify as a gay or bisexual man, or a transgender woman;
- Have male sexual partners within the prior six months
- Resident in the Ehlanzeni District Municipality for at least six months of the year;
- Be physically present in Ehlanzeni for at least two weeks per month
- Self-disclosed receiving an HIV-positive diagnosis in the last 5 years;
- Consent to all serological testing for HIV antibodies, ART analytes, and HIV RNA
- Consent for study staff to review participants' clinical records;
- Consent to the randomization process.
You may not qualify if:
- Inability to provide written informed consent for participation, including being under the influence of alcohol or drugs.
- Inability to provide laboratory or documentary evidence of HIV diagnosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of California, San Franciscolead
- ANOVA Health Institutecollaborator
- National Institutes of Health (NIH)collaborator
Study Sites (1)
Anova Health Institute
Mbombela, Mpumalanga, South Africa
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sheri Lippman, PhD
University of California, San Francsico
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 24, 2017
First Posted
March 30, 2018
Study Start
September 21, 2017
Primary Completion
June 29, 2018
Study Completion
June 29, 2018
Last Updated
February 5, 2020
Record last verified: 2020-02
Data Sharing
- IPD Sharing
- Will not share